Joining the home of Streptomyces research; Introducing Professor Matt Hutchings – The John Innes Centre

Posted on by

Within a year of the John Innes Centre moving to Norwich in 1967, we were joined by Sir David Hopwood, beginning over 50 years of research into the bacteria Streptomyces.

Half a decade on, we welcome the latest group to join an ongoing quest to understand something so crucial to human health and medicine, led by Professor Matt Hutchings.

We caught up with Matt to understand who he is, what his group will be working on and how he became a leading microbial scientist.

Until I was about 15 I wasnt really interested in anything other than sport and drumming. Then, my aunt gave me a book called DNA for Beginners and I read about the discovery of the structure of DNA and the molecular machines involved in transcription and translation of DNA. Ive been hooked ever since.

Ive been interested in microbiology since I did my PhD and increasingly I want to understand how microbes live and survive in natural environments and how they interact with each other and with plants and animals rather than simply studying them on their own on agar plates.

I studyStreptomycesbacteria because they are so important to humans despite more than 50 years of ground-breakingStreptomycesresearch at the John Innes Centre, we are only just developing the tools we need to study these bacteria in the wild.

My work is focussed in understanding the roles ofStreptomycesand their specialised metabolites, which are small molecules that most likely mediate interactions with other microbes, animals and plants in their natural soil environment. However, we still do not fully understand their functions in nature.

Streptomycesbacteria make lots of specialised metabolites that are widely used in human medicine as antibiotics, immunosuppressants, antiparasitic and anticancer drugs.

The genomes ofStreptomycesbacteria, and many other microbes, contain the instructions for making many more specialised metabolites than they actually make when we grow them in the lab. This is presumably because they are required for competition and survival in their natural environment but not when growing in nice, rich, warm culture media.

I want to understand what they are used for in nature, how these bacteria interact with other organisms and to identify the environmental signals that activate production of all their specialised metabolites.

The results from this work would enable us and others to discover many new molecules that could be useful in medicine and also to use these bacteria as plant probiotics so we can reduce the use of agrochemicals that are harmful to the environment.

The John Innes Centre is the home ofStreptomycesresearch and has many brilliant plant scientists, microbiologists and chemists as well as world-leading research facilities. This makes it the ideal place to do research, particularly since I want to study the interactions betweenStreptomycesbacteria and plants.

I feel fortunate and humbled to be following in the footsteps of Sir David Hopwood, Keith Chater, Mervyn Bibb and Mark Buttner and to work with some many brilliant colleagues. I hope that together we can gain new insights into the ecology of these amazing bacteria.

See the original post here:

Joining the home of Streptomyces research; Introducing Professor Matt Hutchings - The John Innes Centre

Scientists Create Cell Atlas of Gene Activity Information of IPF and COPD Patients – Pulmonary Fibrosis News

Posted on by

Scientists created an online cell atlas containing information on the gene activity of more than 300,000 lung cells taken from patients with idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

The new atlas adds to the knowledge of the complex cellular and molecular mechanisms involved in both diseases, and may assist in the development of new therapies, investigators noted.

Analyses leading up to the creation of the cell atlas were reported in the study, Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis, published in the journal Science Advances.

Although studies in animal models of lung disorders have led to important advances in the understanding of pulmonary fibrosis and COPD, the knowledge of the molecular and cellular mechanisms underlying these diseases is still limited.

In an effort to expand this knowledge, researchers at Yale School of Medicine and their colleagues set out to create a cell atlas containing the genetic profile of a large number of lung cells taken from patients with either IPF or COPD.

As a first step, researchers isolated individual cells from different parts of the lungs, and then used a technique called single-cell RNA sequencing (scRNA-seq) to examine all RNA molecules, or transcripts, produced from active genes on each individual cell.

Through this process, the team analyzed 312,928 cells taken from 32 patients with IPF and 18 with COPD, creating the largest single-cell gene expression (activity) dataset in patients with chronic lung disorders to date. As controls, cells from 28 donor lungs also were analyzed.

This is a technological accomplishment and is a new perspective on the two diseases, but it is also the starting point for analysis that will lead to a better understanding of the disease and the development of therapy, Ivan Rosas, MD, said in a news story. Rosas is chief of pulmonary, critical care and sleep medicine in the Department of Medicine at Baylor College of Medicine, and co-senior author of the study.

When investigators compared the different populations of cells isolated from patients, they found that cells lining the surface of the lungs (epithelial cells) in IPF patients were very different from those found in COPD patients. The team also discovered a new population of abnormal epithelial cells in the lungs of IPF patients that never had been described before.

Additionally, they found IPF patients had an excessive number of a sub-type of cells forming the lining of blood vessels in the lungs, called vascular endothelial cells.

When we analyzed the data we were surprised by how dramatically different were cells obtained from patients with PF from all other lungs we actually found cells that were not described before, and this may have significant implications on diagnosis and management for the disease, saidNaftali Kaminski, MD, chief of pulmonary, critical care and sleep medicine at Yale, and co-senior author of the study.

The identification and detailed description of aberrant cell populations in the IPF lung may lead to identification of novel, cell type-specific therapies and biomarkers. Last, our IPF cell atlas provides an interactive and highly accessible resource to allow the exploration of cell specific changes in gene expression in lung health and disease and thus accelerate discovery and translation, the researchers wrote.

Rosas began the study while at Harvard Medical School, and now will continue it at Baylor.

Chronic lung diseases are one of the leading causes of morbidity and death in diagnosed patients, but this innovative technology is the starting point for more pointed research in terms of the pathogenesis and the mechanisms of the disease and also the potential therapy that could be derived from the information, Rosas said.

The cell atlas is available to the public, allowing other researchers to conduct their own independent research based on these data.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that made up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 110

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Link:

Scientists Create Cell Atlas of Gene Activity Information of IPF and COPD Patients - Pulmonary Fibrosis News

Sexism pushed Rosalind Franklin toward the scientific sidelines during her short life, but her work still shines on her 100th birthday -…

Posted on by

Rosalind Franklin at age 25. Elliott & Fry/ National Portrait Gallery, London, CC BY-NC-ND

Richard Gunderman, Indiana University

What do coal, viruses and DNA have in common? The structures of each the predominant power source of the early 20th century, one of the most remarkable forms of life on Earth and the master molecule of heredity were all elucidated by one person. Her name was Rosalind Franklin, and the story of her triumph over sexism and rise to scientific greatness is made even more remarkable by the fact that she lived only 37 years.

In Franklins day, sexism ran rampant in science. Her own father, judging science no career for a woman, actively discouraged her aspirations. Her doctoral supervisor at Cambridge, eventual Nobel Laureate Ronald G.W. Norrish, called her stubborn and difficult to supervise and offered little support. James Watson, whose Nobel Prize hinged in large part on her work, referred to her in his memoir as Rosy (against her preference), and stated that, because of her belligerent moods, colleagues knew she either had to go or be put in her place.

Despite the attitudes of those around her, Franklin maintained her scientific acumen and thirst for knowledge, crucially contributing to one of the greatest discoveries of the 20th century.

Franklin was born in London on July 25, 1920 to a prominent family. Her great uncle served in the British Cabinet, and her father was a banker and science educator.

Franklin was an outstanding student. She received a scholarship to Cambridge, where she earned honors on her examinations and won a research fellowship. A lack of rapport with her supervisor, Norrish, drove her from his lab, and she ended up conducting groundbreaking research for her Ph.D. thesis on the molecular structure of coal.

Franklin then moved to Paris, where she studied X-ray crystallography, a powerful means of inferring the structure of molecules from how they bend beams of X-rays. She produced a number of important articles before returning to the U.K.

[Deep knowledge, daily. [Sign up for The Conversations newsletter]

Assigned to work on the structure of DNA in her new position at Kings College London, she applied her knowledge of X-ray diffraction and created crucial images of its molecular structure. At the time, determining DNAs structure was one of sciences holy grails.

Recalling a moment in 1953, Watson described first seeing one of Franklins images of the DNA molecule, known as Photograph 51:

The instant I saw the picture my mouth fell open and my pulse began to race. The pattern was unbelievably simpler from those obtained previously. Moreover, the black cross of reflections which dominated the picture could only arise from a helical structure.

Watson and his Cambridge collaborator and eventual fellow Nobel Laureate Francis Crick were not doing laboratory research on the structure of DNA, but they were actively attempting to build a model of it. Franklins image provided them with a breakthrough. Franklin was a cautious scientist, believing that modeling should await airtight scientific evidence. But Watson and Crick were less hesitant and became convinced that their double helix model must be correct.

In 1953, when Watson and Crick announced their now famous double helix model for DNA, tensions at Kings College were driving Franklin to Birkbeck College. She joined John Bernal, an X-ray crystallographer known for promoting the careers of women.

There Franklin worked on characterizing the structure of RNA, another key information-bearing molecule in living organisms. She also studied the tobacco mosaic virus, the first virus shown to be harmful to a living organism, the tobacco plant.

During a trip to the U.S. in 1956, Franklin first noticed that she was having difficulty fitting into her clothes. Upon her return to London, she was diagnosed with ovarian cancer, the result of mutations in the DNA of her own cells. Yet she did not let her illness interfere with her work and published a half dozen or more scientific papers in both 1956 and 1957. She died in April of 1958.

Franklin faced sexism for much of her professional life in science. Watson repeatedly described her in sexist terms in The Double Helix, criticizing her choice not to emphasize her feminine qualities and her lack of even a mild interest in clothes. Moreover, he and Crick chose not to reveal the extent to which their model depended on her DNA photograph.

Even in this atmosphere, Franklin was a great scientist, as captured in this passage from her obituary, composed by her mentor, Bernal:

She was distinguished by extreme clarity and perfection in everything she undertook. Her photographs are among the most beautiful X-ray photographs of any substance ever taken. Her early death is a great loss to science.

Franklin certainly did not sink into obscurity.

One of her students, eventual Nobelist Aaron Klug, continued her work, helping to develop a new form of crystallography that relies on electrons instead of X-rays and advancing the understanding of the structure of viruses.

And of course initial skepticism about a double helix structure for DNA waned. Watson, Crick and another X-ray crystallography researcher at Kings College, Maurice Wilkins, received the Nobel Prize in Physiology or Medicine in 1962 for its identification.

Many have wondered why Franklin did not receive the Nobel Prize. First, she was never nominated, perhaps in part because of her gender. Another problem was the fact that the prize cannot be divided among more than three people, though some historians have argued that she deserved it more than Wilkins. Perhaps the most decisive reason is that Nobel Prizes are not awarded posthumously.

Franklin has been memorialized in many ways. Kings College and Cambridge University both created residence halls in her name, and Birkbeck established the Rosalind Franklin Laboratory. Her portrait now hangs next to those of Watson, Crick and Wilkins in the National Portrait Gallery in London.

And outside of Chicago is the Rosalind Franklin University of Medicine and Science, which uses photograph 51 as its logo.

Franklin saw herself less as a female scientific pioneer than as a researcher whose work should be assessed purely in the light of her scientific contributions. Although she was not focused on gender, perhaps her greatest and most enduring legacy is the many women who have been inspired by her example to pursue scientific careers.

Richard Gunderman, Chancellors Professor of Medicine, Liberal Arts, and Philanthropy, Indiana University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read more:

Sexism pushed Rosalind Franklin toward the scientific sidelines during her short life, but her work still shines on her 100th birthday -...

Bioinformatics Market 2020: Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast- 2025 – Cole of Duty

Posted on by

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Accelrys Inc., ID Business Solutions, Ltd., Affymetrix Inc., CLC bio A/S, Agilent Technologies Inc., GenoLogics Life Sciences Software, Inc., Life Technologies Corporation, and Illumina Inc. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Global Bioinformatics Market is expected to be around US$ 17 Billion by 2025 at a CAGR of 14% in the given forecast period.

Browse Full Report: https://www.marketresearchengine.com/bioinformatics-market-report

The Global Bioinformatics Market is segmented on the lines of its sector, product and service application and regional. Based on sector segmentation it covers medical biotechnology, animal biotechnology, academics, agricultural biotechnology, forensic biotechnology, environmental biotechnology and other sectors. Under product and service segmentation it covers knowledge management tools, bioinformatics services and bioinformatics platforms. Based on application segmentation it covers genomics, proteomics, chemoinformatics and drug design, transcriptomics, molecular phylogenetics, metabolomics and other applications. The Global Bioinformatics Marketis geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

Bioinformatics marketis the mixture of both biology and information technology. It is generally used in organizing the biological data in the sector of medical research and development of medicines and drugs. Bioinformatics relates with storage, annotation, recording, analysis and retrieval of nucleic acid sequence, structural information and protein sequence. It is used in different sectors and applications in medicine and biology including molecule studies, protective drugs, chromosome therapy, drug innovations, biotechnology and forensic analysis of microorganisms. The boom of the bioinformatics is being augmented by means of the growing function of IT in the healthcare zone in conjunction with robust technical advancements. The employment of IT has enabled easy processing, storage, retrieval, access of data.

The Global Bioinformatics Market has been segmented as below:

The Global Bioinformatics Market this market is segmented on the basis of Sector Analysis, Product and Service Analysis, Application Analysis and Regional Analysis.

By Sector Analysis this market is segmented on the basis of Medical Biotechnology, Animal Biotechnology, Academics, Agricultural Biotechnology, Forensic Biotechnology, Environmental Biotechnology and Other Sectors.By Product and Service Analysis this market is segmented on the basis of Knowledge Management Tools, Bioinformatics Services and Bioinformatics Platforms.By Application Analysis this market is segmented on the basis of Genomics, Proteomics, Chemoinformatics and Drug Design, Transcriptomics, Molecular Phylogenetics, Metabolomics and Other Applications.By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

The scope of the report includes a detailed study of global and regional markets for Global Bioinformatics Market with the reasons given for variations in the growth of the industry in certain regions.

The major driving factors of Global Bioinformatics Market are as follows:

The restrainingfactors of Global Bioinformatics Market are as follows:

This report provides:

1) An overview of the global market for Bioinformatics and related technologies.

2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024.

3) Identifications of new market opportunities and targeted promotional plans for Global Bioinformatics Market.

4) Discussion of research and development, and the demand for new products and new applications.

5) Comprehensive company profiles of major players in the industry.

Request Sample Report: https://www.marketresearchengine.com/bioinformatics-market-report

Table of Contents

1 INTRODUCTION

2 Research Methodology

2.1 Research Data2.2 Market Size Estimation2.3 Market Breakdown and Data Triangulation2.3.1 Key Data From Secondary Sources2.3.2 Key Data From Primary Sources2.3.2.1 Key Industry Insights2.3.3 Assumptions for the Study2.4 Macroeconomic Factor Analysis2.4.1 Introduction2.4.2 Demand-Side Analysis2.4.2.1 Healthcare Expenditure Pattern2.4.3 Supply-Side Analysis2.4.3.1 Number of New Product Launches

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Bioinformatics Market, By Sector

7 Bioinformatics Market, By Products & Services

8 Bioinformatics Market, By Application

9 Bioinformatics Market, By Region

10 Competitive Landscape

11 Company Profiles

11.1 Introduction

11.2 Illumina, Inc.

11.3 Thermo Fisher Scientific Inc.

11.4 Qiagen N.V.

11.5 Agilent Technologies

11.6 Applied Biological Materials (ABM)

11.7 Biomax Informatics Ag

11.8 DNAnexus, Inc.

11.9 ID Business Solutions Ltd.

11.10 Perkinelmer, Inc.

11.11 Waters Corporation

Other Related Market Research Reports:

Biofertilizer Market Key Manufactures and Opportunity Analysis By 2022

Bioburden Testing Market is Expected to Grow US$ 907 Million By 2022

Bio Solids Market Key Manufactures and Opportunity Analysis By 2022

Media Contact

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com

See original here:

Bioinformatics Market 2020: Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast- 2025 - Cole of Duty

Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations |…

Posted on by

DetailsCategory: AntibodiesPublished on Wednesday, 22 July 2020 11:28Hits: 138

- $32.5M Series A Financing Led by Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners -

- Registration-Enabling Phase 2 CRESTONE Study Now Enrolling Patients with Solid Tumors of Any Origin that have an NRG1 Gene Fusion -

- CRESTONE Enrollment Enhanced Through Strategic Partnerships with Next Generation Sequencing Diagnostic Providers Including Ashion Analytics, Strata Oncology, and Tempus to Advance Patient Enrollment Practices for Genomically-driven, Tumor-agnostic Clinical Trials -

NEW YORK, NY, USA I July 21, 2020 I Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the launch of the Company with a $32.5M Series A financing, initiation of the Phase 2 CRESTONE study, and new partnerships with Next Generation Sequencing diagnostic providers including Ashion Analytics, Strata Oncology, and Tempus to explore innovative models for real-time identification, patient referral, and enrollment of patients with tumors driven by rare genomic alterations. The Series A financing was led by Aisling Capital and a syndicate of investors including Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners.

"At Elevation Oncology, we envision a future in which each unique genomic testing result can be matched with a purpose-built precision medicine and bring clarity to the patient treatment journey. Focused drug development paired with open collaboration will be instrumental for our industry to fully realize the potential of precision medicine for all patients with cancer," said Shawn Leland, PharmD, RPh, Founder and Chief Business Officer of Elevation Oncology. "With our lead development program, seribantumab, and the partnerships announced today, we are taking our first steps toward this future."

Seribantumab and the Tumor-agnostic CRESTONE Study

Seribantumab is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (ERBB3 or HER3). HER3 is traditionally activated through binding of its primary ligand, neuregulin-1 (NRG1). The NRG1 gene fusion is a rare genomic alteration that combines NRG1 with another partner gene to create chimeric NRG1 "fusion proteins."

Seribantumab was acquired in 2019 by Elevation Oncology, and the development program builds on prior clinical experience from over 800 patients demonstrating consistent safety and tolerability. Previous clinical trials with seribantumab did not select for tumors with an NRG1 fusion. The CRESTONE study leverages seribantumab's rational design with recent discoveries on the significance of the NRG1 gene fusion and improvements in diagnostic sensitivity. Novel preclinical data generated by Elevation Oncology demonstrating the ability of seribantumab to prevent the activation of HER3 signaling in NRG1 fusion models are supportive of CRESTONE and are expected to be released in publications and at scientific conferences later this year.

Although rare, NRG1 gene fusions are oncogenic drivers that can be found in a variety of solid tumors, including lung, pancreatic, gallbladder, breast, ovarian, colorectal, and neuroendocrine cancers, and sarcomas. Importantly, NRG1 gene fusions are mutually exclusive with other known driver mutations and are considered a unique oncogenic driver event essential for tumor cell survival. Following recent regulatory approvals of tumor-agnostic treatments associated with oncogenic drivers, CRESTONE is designed as a registration-enabling Phase 2 "basket trial" to evaluate the efficacy and safety of seribantumab in patients with any solid tumor that harbor an NRG1 fusion.

"Genomic testing and matched precision therapeutics are creating a revolution in oncology development and regulatory approval paths," said Lori Kunkel, MD, Chair of the Elevation Oncology Scientific Advisory Board and former Chief Medical Officer LOXO Oncology. "The FDA has recently approved several oncology therapeutics for tumor-agnostic indications. I am encouraged to see the evolution in our understanding of how to achieve better clinical outcomes to address the unmet clinical need among patients with a genomically defined cancer, regardless of its tissue of origin. The CRESTONE study potentially expands the actionability of genomic tests to tumors with an NRG1 fusion and is a promising approach for furthering this genomically-driven tumor-agnostic development pathway."

Innovative Models for Patient Enrollment

Sarah Cannon Research Institute(Sarah Cannon) has been selected as the first strategic site for CRESTONE and is open and enrolling patients today. Sarah Cannon's world class clinical research leadership and insights as well as additional prospectively selected clinical sites are foundational to ensuring rigorous study conduct.

"Identifying potential driver alterations, such as NRG1 gene fusions, enables us to approach cancer treatment in a more targeted way," said David Spigel, MD, Chief Scientific Officer, Sarah Cannon Research Institute at Tennessee Oncology and one of the investigators of the CRESTONE study. "Today, all cancer patients facing a treatment decision without clear standard of care should consider comprehensive genomic testing for their tumor. Collaborations across the healthcare ecosystem help to ensure that the value of each genomic test is maximized and to expand access to critical treatment opportunities for patients."

Diagnostic partnerships will enhance traditional patient enrollment in the CRESTONE study through real-time, nationwide identification of NRG1 fusion positive patients withintheAshion, Strata Oncology, Tempus, and other partner networks. Through various partnership models, patients may also be enrolled in CRESTONE through active referral to current strategic sites or "just-in-time" site initiation.

These innovative models address specific challenges encountered by genomically-driven, tumor-agnostic trials such as the rarity of genomic driver alterations and the impracticality of comprehensive clinical site coverage by both geography and organ-system of study. In addition, these models may reduce the burden on patients by minimizing the number of diagnostic tests they may need and maximizing the treatment opportunities available to them, regardless of where they may live. Bringing clinical trials to patients using the "just-in-time" site initiation model can further help to minimize travel and keep patients safe in the face of ongoing travel restrictions due to COVID-19.

"With the strong backing of a dynamic and experienced investor syndicate, Elevation Oncology is well positioned to execute on our mission of delivering precision medicines to physicians and their patients with cancer," said Steve Elms, Chairman and Interim Chief Executive Officer of Elevation Oncology and Managing Partner of Aisling Capital. "Our development approach to seribantumab sets the stage for our broader vision: the elevation of precision medicine to the forefront of every patient journey through building a collaborative industry-wide ecosystem. Together with diagnostic developers, clinical researchers, patient advocates, and the Elevation Oncology team, we are looking to build a pipeline of precision oncology medicines that can amplify each other's efforts towards our shared goal of improving patient outcomes."

About Elevation Oncology

Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Together with our peers we work towards a future in which each unique test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion. Details on CRESTONE are available at http://www.NRG1fusion.com. For more information visit http://www.ElevationOncology.com.

About Ashion Analytics

Ashion Analytics, LLC, is a CLIA-certified and CAP-accredited clinical laboratory that uses advanced genomic technologies to offer a wide range of testing capabilities to assist physicians, health systems, research and commercial partners to provide precision cancer treatments. Ashion was developed and launched by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.

About Strata Oncology

Strata Oncology, Inc. is a precision medicine company dedicated to transforming cancer care by building a platform to systematize precision oncology across a network of health systems and biopharma companies. Strata Oncology empowers health systems to deliver a comprehensive, system-wide precision oncology program that integrates cutting-edge tumor molecular profiling and a portfolio of biomarker-guided with routine care, so that all patients with advanced cancer have the opportunity to benefit. This large network of trial-ready health systems provides a mechanism to rapidly and predictably enroll precision therapy trials. For more information visitwww.strataoncology.com.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Additionally, the TIME TrialNetwork leverages a unique and comprehensive infrastructure to bring the right clinical trials to the right patients in under two weeks.The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

SOURCE: Elevation Oncology

See the original post here:

Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations |...

Coronavirus vaccine Who is Irish scientist Adrian Hill, where did he grow up & how did he lead team to b – The Irish Sun

Posted on by

ADRIAN Hill is the leading scientist among the team of researchers who are striving to develop a working vaccine for Covid-19 through clinical trials.

The Irish doctor's coronavirus vaccine has been described by WHO as the leading candidate for a working vaccine.

5

5

Here's everything we know about Dr Adrian Hill and his work to find a cure for coronavirus.

The 62-year-old doctor grew up in Ranelagh in Dublin and attended Belvedere College.

He then went on to study medicine at Trinity College and transferred to the University of Oxford in 1978 where he completed his medical degree in 1982.

5

During his time as a student in the 1980s, Dr Hill developed a fascination with vaccines and tropical diseases such as malaria.

His interest began when he visited his uncle who was a missionary priest working in a hospital during the civil war in Zimbabwe.

Adrian continued his studies in Oxford until he graduated with a Doctor of Philosophy degree in 1986.

In 1988, he joined the Weatherall Institute of Molecular Medicine at Oxford and began working on immunogenetics in West Africa.

From there he became the leader of an academic course on Human and Animal Vaccinology at Oxford and is now the Director of the Jenner Institute, an Oxford institute which develops vaccines and carries out clinical trials for diseases.

He also heads a group at the Wellcome Trust Centre for Human Genetics which studies genetic susceptibility factors for common bacterial diseases.

The Irish vaccinologist has two children with his former wife, Sunetra Guptta who is a well known Indian novelist and professor of theoretical epidemiology at the University of Oxford with an interest in infectious disease agents.

Dr Hill established his growing reputation for his work on an Ebola vaccine in 2014.

His team took the lead in the first clinical trial of an Ebola vaccine which targeted the outbreak of the disease in West Africa.

5

The team also developed malaria vaccines that have been tested in clinical trials and is one of the most promising vaccines against the disease.

Adrian is at the forefront of driving the power of medicine to provide healthcare for some of the poorest communities around the world.

In 2014, Dr Hill gave a statement saying: "Witnessing the events in Africa makes it clear that developing new drugs and vaccines against Ebola should now be an urgent priority.

"It is tremendous that so many people have worked hard to make this trial happen in short time, and I am enormously grateful to those volunteers who have come forward to take part and to the funders for supporting this trial so quickly.

"These are initial safety trials of the vaccine and it will be some time before we know whether the vaccine could protect people against Ebola. But we are optimistic that the candidate vaccine may prove useful against the disease in the future."

He has expertise in vaccines for Ebola and malaria, immunology and vaccinology of infectious diseases, human genetics particularly susceptibility to tuberculosis, leprosy, sepsis and other bacterial diseases as well as vaccines against intracellular pathogens.

Dr Hill and his team have now shifted their focused onto Covid-19 and are now the leading candidates for a working vaccine.

The Oxford Covid-19 vaccine trial is being run by the Jenner Institute and Oxford Vaccine Group.

5

While Professor Hill is leading the team, other keys members include Prof. Sarah Gilbert, Prof. Andrew Pollard, Prof. Teresa Lambe, Dr Sandy Douglas and Prof. Catherine Green.

The team began developing a vaccine against the coronavirus on January 20, 2020 and have shown great success in recent weeks.

The results of the first phase of the trial were published on Monday in The Lancet, a scientific journal, and indicate no early safety concerns and induces strong immune responses in both parts of the immune system.

The vaccine provoked a T cell response within 14 days of vaccination - this means white blood cells that can attack cells infected with the coronavirus responded within two weeks.

Additionally, there was an antibody response within 28 days - antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted.

During the study participants who received the vaccine had detectable neutralising antibodies, which have been suggested by researchers as important for protection.

Scientists said it produced a reaction in people aged 18 to 55 that lasted at least two months after they were immunised.

Prof Hill said: What were reporting today is the result of a phase 1 trial in over 1,000 people looking at how well this vaccine performs both in terms of its safety, which is good and its immune responses which are pretty exciting.

Hill said that larger trials evaluating the vaccines effectiveness, involving about 10,000 people in the UK as well as participants in South Africa and Brazil are still underway.

Another big trial is hoping to start in the US soon, aiming to enroll about 30,000 people.The next step in studying the vaccine is to confirm that it can effectively protect against Covid-19 infection.

Dr Hill's vaccine will now potentially move forward to more trials where researchers will deliberately attempt to infect test subjects with the virus after they have been given a dose of the vaccine.

Oxford is working with multinational biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the Covid-19 vaccine.

'real heroes'Tributes paid as hero doctor sadly loses battle against Covid-19 in ICU

TRAVEL fearsTravel through airports not on green list ok if you don't leave, Coveney says

Jackpot!Lotto urge EuroMillions players to check emails as one player wins 49.5m

DEAL BLASTMicheal Martin under fire for striking 'bad deal' for EU Covid-19 rescue fund

Green Light15 countries on highly awaited Green List revealed

Latest

whopping winHunt is on to find Irish Euromillions player who won 49.5m jackpot

The project has received 84million 75million) of government funding to help accelerate the vaccines development.

The timeline for a phase three trial depends on whether enough participants have been exposed to the coronavirus in everyday life, which should reveal whether those who have received the vaccine are protected.

This can take months depending on infection levels in the community.

See more here:

Coronavirus vaccine Who is Irish scientist Adrian Hill, where did he grow up & how did he lead team to b - The Irish Sun

Nuclear Medicine or Radiopharmaceuticals Market Innovative Report Growth impact over the forecast year 2020 to 2027 – Cole of Duty

Posted on by

The New Report Titled as Nuclear Medicine or Radiopharmaceuticals Market published by Reportspedia, covers the market landscape and its evolution predictions during the forecast period. The report objectives to provide an overview of global Nuclear Medicine or Radiopharmaceuticals Market with detailed market segmentation by solution, security type, application and geography. The Nuclear Medicine or Radiopharmaceuticals Market is anticipated to eyewitness high growth during the forecast period. The report delivers key statistics on the market status of the leading market players and deals key trends and opportunities in the market.

Request For Free Sample Report: @ https://www.reportspedia.com/report/life-sciences/2015-2027-global-nuclear-medicine-or-radiopharmaceuticals-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58216#request_sample

This research report also includes profiles of major companies operating in the global market. Some of the prominent players operating in the Global Nuclear Medicine or Radiopharmaceuticals Market are:

Lantheus Medical Imaging, Inc.Advanced Accelerator Applications S.A.Mallinckrodt PLCBayer AGCardinal Health, Inc.Bracco Imaging S.P.AIba MolecularGE HealthcareNordion, Inc.Eczacibasi-Monrol Nuclear Products

The Nuclear Medicine or Radiopharmaceuticals Market for the regions covers North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Regional breakdown has been done based on the current and forthcoming trends in the global Nuclear Medicine or Radiopharmaceuticals Market along with the discrete application segment across all the projecting region.

Ask For Discount: https://www.reportspedia.com/discount_inquiry/discount/58216

The Type Coverage in the Market are:

Diagnostic Nuclear MedicineTherapeutic Nuclear Medicine/ Radiopharmaceuticals

Market Segment by Applications, covers:

Diagnostic ApplicationsTherapeutic Applications

Some Major TOC Points:

Chapter 1. Nuclear Medicine or Radiopharmaceuticals Market Report Overview

Chapter 2. Global Nuclear Medicine or Radiopharmaceuticals Market Growth Trends

Chapter 3. Market Share by Key Players

Chapter 4. Nuclear Medicine or Radiopharmaceuticals Market Breakdown Data by Type and Application

Chapter 5. Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Nuclear Medicine or Radiopharmaceuticals Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Force

Continue for TOC

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.reportspedia.com/report/life-sciences/2015-2027-global-nuclear-medicine-or-radiopharmaceuticals-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58216#inquiry_before_buying

Key questions Answered in this Nuclear Medicine or Radiopharmaceuticals Market Report:

What will be the Nuclear Medicine or Radiopharmaceuticals Market growth rate and value in 2020?

What are the key market predictions?

What is the major factors of driving this sector?

What are the situations to market growth?

Major factors covered in the report:

Global Nuclear Medicine or Radiopharmaceuticals Market summary

Economic Impact on the Industry

Nuclear Medicine or Radiopharmaceuticals Market Competition in terms of Manufacturers

Nuclear Medicine or Radiopharmaceuticals Market Analysis by Application

Marketing Strategy comprehension, Distributors and Traders

Study on Market Research Factors

Table of Content & Report Detail @ https://www.reportspedia.com/report/life-sciences/2015-2027-global-nuclear-medicine-or-radiopharmaceuticals-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58216#table_of_contents

See the article here:

Nuclear Medicine or Radiopharmaceuticals Market Innovative Report Growth impact over the forecast year 2020 to 2027 - Cole of Duty

North Oaks Sports Medicine recognizes 2019-2020 Student-Athletes of the Year, both from Albany High School – The Advocate

Posted on by

HAMMOND North Oaks Sports Medicine certified athletic trainers join with the providers of North Oaks Orthopaedic Specialty Center to announce the selection of Albany High Schools Abrielle Ochsner and Caleb Puma as 2019-20 Student-Athletes of the Year.

Ochsner and Puma were selected from all Student-Athletes of the Month for both Tangipahoa and Livingston parishes based on the number of votes received via an online poll conducted June 30 to July 9 at northoaks.org.

Rising junior Abrielle has cheered for the Hornets for two years.

Cheer Sponsor Deloy Duhon said Abrielle, an honor student, is known for her kindness.

On top of taking high school algebra, biology, English and human geography advanced placement and honors classes,Abrielle is a student of Southeastern Louisiana Universitys dual enrollment program and was recognized on the presidents list.

She is active in Beta Club and the Student Government Association. She served as sophomore representative this past school year.

Recent honor graduate Caleb played basketball for the Hornets all four years of high school. As a guard in his senior year, he averaged 18 points per game and received honorable mention as an All-Parish selection.

In May,Caleb committed to play basketball at Centenary College in Shreveport, where he plans to study business management.

Boys basketball coach Chris Carter saidCaleb often shares his love of the game mentoring younger players.

In his spare time, Caleb mentors elementary and middle school student-athletes. He imparts the importance of hard work and a positive attitude to achieving their goals and becoming a role model to their peers, Carter said.

Calebparticipates in community outreach and fundraising activities through the Legacy Youth Group of his church, New Beginnings Outreach in Holden.

To learn about North Oaks Sports Medicine or the Student-Athlete of the Season/Year program, visit northoaks.org/sportsmedicine or contact North Oaks Public Relations at (985) 230-6647.

Success! An email has been sent with a link to confirm list signup.

Error! There was an error processing your request.

Read more here:

North Oaks Sports Medicine recognizes 2019-2020 Student-Athletes of the Year, both from Albany High School - The Advocate

End tariffs on medicine to improve access Philip Stevens and Nilanjan Banik – Malay Mail

Posted on by

JULY 22 While researchers in universities and private-sector laboratories work round-the-clock for new treatments and vaccines for Covid-19, physicians rely on a broad cabinet of older medicines to help patients through their darkest hour.

Unprecedented demand caused by hospitals stockpiling basic medicines such as antibiotics, painkillers, sedatives, and corticosteroids has caused global shortages and surging prices.

Indias drug regulators temporary green light for a 50 per cent increase in price of the blood thinner heparin is one example. Meanwhile, Covid-related pressures have seen Pakistans regulator approve a 7 per cent increase for essential drugs. In the UK, the price of basic painkillers has leapt 30 per cent since the start of the pandemic.

These are unusual times when manufacturers are struggling to meet demand. But some governments are adding to the problem by levying needless import tariffs on medicines.

Most countries, including Malaysia, levy no tariffs on imported medicines. But many middle-income countries do.

At 20 per cent, Pakistan boasts the highest rate globally, according to a report published this week by Geneva Network. More, the South Asian trio of Nepal, Pakistan and India have the top three tariff rates (10 per cent in India), the study finds. Latin America is another medicines tariff hotspot, with Argentina and Brazil levying average tariffs of close to 10 per cent.

Pharmaceutical manufacturing value chains are increasingly globalised; even low tariffs have a cumulative impact on a products end price, ultimately paid by patients.

A 2017studyby the European Centre for International Political Economy found that tariffs add a cumulative burden of up to US$6.2 billion (RM264.42 billion) per year in China. In Brazil and India, patients may pay up to 80 per cent more than the ex-factory sales price due to tariffs.

Abolishing these tariffs would deliver to patients aggregate savings of up to US$6.2 billion in China, US$2.8 billion in Russia, US$2.6 billion in Brazil and US$737 millio in India, the study says.

Existing medicines are one issue, but Covid-19 is a newly identified disease; a new vaccine is the only long-term solution. Its invention, mass manufacture and rapid distribution globally are all critical.

Tariffs will hinder the rapid dissemination and uptake of the vaccine, resulting in needless suffering and death and economic hardship. While most countries enjoy tariff-free regimes for vaccines, certain others needlessly inflate their price through import tariffs. India again tops the table globally, with vaccine tariffs at 10 per cent. Pakistan and Bolivia are among a clutch of countries that impose vaccine tariffs of 5 per cent.

Beyond medicines, Covid essentials from hand soap to ventilators are more expensive thanks to tariffs. According to the World Trade Organisation (WTO), the average applied tariff for hand soap is 17 per cent and some countries apply tariffs as high as 65 per cent.

Five Latin American countries (Ecuador, Bolivia, Venezuela, Brazil, and Argentina) have the highest tariffs on facemasks, from 17 per cent to 55 per cent. Brazil, Argentina, and Venezuela levy a 14 per cent import tariff on ventilators; in India its 10 per cent.

Some governments Pakistan, Brazil, Columbia and Norway among them have shown leadership by temporarily exempting Covid-19 related medicines, vaccines and medical supplies from import duties and taxes.

Meanwhile, Apec governments are discussing proposals to eliminate for at least one year taxes and tariffs on Covid-19 medical products.

Malaysia has also temporarily eliminated import tariffs on Covid-related supplies such as face masks, soap and protective equipment and ventilators.

While positive, such reforms are only temporary. They create uncertainty for exporters over the long-term direction of individual markets. They undermine preparation for future pandemics by medicine manufacturers.

Governments should commit to permanent tariff reductions on medicines, vaccines, and medical supplies through legally binding WTO commitments.

Most obviously, more WTO members should back the organisations Pharmaceutical Agreement (also known as Zero for Zero) as swiftly as possible, bolstering the group of 34 countries who have already agreed to abolish tariffs on medicines for all WTO members.

Notably absent here are India, Brazil, South Africa, Russia, China and of course Malaysia.

For Malaysia, non-membership of the WTO Pharmaceutical Agreement means any future government could increase tariffs on medicines, to the detriment of patients. Joining the Agreement would mean permanent duty-free medicines in perpetuity.

This is not only vital for beating Covid-19, but also a positive legacy for the future.

* Philip Stevens is Senior Fellow at IDEAS Malaysia. Nilanjan Banik is Professor of Economics at Bennett University, New Delhi, India.

** This is the personal opinion of the writer(s) or organisation(s) and does not necessarily represent the views of Malay Mail.

More here:

End tariffs on medicine to improve access Philip Stevens and Nilanjan Banik - Malay Mail

Narrative Medicine Challenges Med Students to Discover The Person Within The Patient – The Roanoke Star

Posted on by

Brian and Cynthia (Cyndy) Unwin team teach the narrative medicine elective for students at the medical school.

Brian and Cyndy Unwin are spouses and team-teach the elective. Brian spent almost three decades in the military, earning his medical degree from the Uniformed Services University, with a focus in family medicine and geriatrics. Later, he served as faculty at the military medical school for nine years. Cyndys background is in elementary and reading education. Ive spent most of my career working with children with literacy difficulties, Cyndy Unwin said. About 20 years ago, I started thinking I might also like to write books for kids. Since then, she has published several childrens books and continues her involvement in childrens literacy.

In 2013, Brian retired from the U.S. Army and the Unwins moved to Roanoke, Virginia, so he could practice with Carilion Clinic and serve as faculty at VTCSOM. Four years ago, Cyndy also began working with the medical students in an advisory role to help them fine-tune their personal statements for residency applications.

When the school began exploring the idea of adding a narrative medicine elective three years ago, leadership asked the Unwins to lead the course, recognizing the couples mix of strengths and backgrounds. It is one of three electives at the school that students can take during the first two years of study. Successful completion of an elective gives students extra credit hours to use in their fourth year, allowing more time to travel for residency interviews or use for vacation. The other two electives are Mindfulness and Medical Spanish.

The electives have been popular for students. I joined narrative medicine because I want to remember why I am doing this, make sure that I develop the skills to always pull my head up from the specifics, and remember that the connection with a patient can be just as important as the medicine provided, said Abra Roberts, a second-year VTCSOM student.

The narrative medicine elective has had three cohorts of students. In addition to reading assignments and class discussion, students complete three narrative projects. The first is a personal memoir. The other two are focused around patient interviews. Students have completed the projects using diverse types of media, including writing, art, music, and drama.

Understanding a patients health narrative is important and part of what it means to take care of someone, said Kian Tehranchi, a fourth-year student at VTCSOM. I think this class will push me to prioritize getting my patients stories in the future.

While medical students receive training in other coursework on how to complete a patient interview in the context of medical care, these assignments require students to dig deeper and reveal more about the patient as a person.

The projects challenged students to apply that idea later in their practice. I learned how to better view a situation from the patients perspective and not to shy away from the difficult questions, said fourth-year student Keri Godbe.

This course has made me realize just how deep the doctor-patient relationship can be and how important it is in the context of care, said third-year student Jacob Hartman-Kenzler. I feel like we were given the chance to pull back the curtain and talk about aspects of medicine that doctors usually arent exposed to until much later in their careers. This course has helped me realize how I want to practice medicine, regardless of specialty, and how I want my patients to feel when theyre in my care.

View original post here:

Narrative Medicine Challenges Med Students to Discover The Person Within The Patient - The Roanoke Star

High Demand for Anti-Aging Medicine from the Millennial Population to Foster the Growth of the Anti-Aging Medicine Market between 2018 2026 – 3rd…

Posted on by

Insights on the Global Anti-Aging Medicine Market

PMR is one of the leading market research companies in India. Our team of research analysts have a deep understanding and knowledge related to the latest market research techniques and use their analytical skills to curate insightful and high-quality market reports. The presented data is collected from credible primary sources including marketing heads, sales managers, product managers, industry experts, and more.

As per the report, the global Anti-Aging Medicine market reached a value of ~US$ XX in 2018 and is likely to surpass a market value of ~US$XX by the end of 2029. Further, the report reveals that the Anti-Aging Medicine market is set to grow at a CAGR of ~XX% during the forecast period (2019-2029)

Request Sample Report @ https://www.persistencemarketresearch.co/samples/26233

Critical doubts related to the Anti-Aging Medicine market addressed in the report:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/26233

Segmentation of the Anti-Aging Medicine market

The report bifurcates the Anti-Aging Medicine market into different segments to provide a clear understanding of the various aspects of the market.

Regional Outlook

The regional outlook section of the report includes vital data such as the current trends, regulatory framework, The Anti-Aging Medicine market study offers critical data including, the sales volume, sales growth, and pricing analysis of the different products in the Anti-Aging Medicine market.

key players in the region.

Some of the players operating in the global anti-aging medicine market are Pfizer, Evolution GmbH, Himalaya Global Holdings Ltd., Cipla Limited, Mylan Laboratories, Novartis, Merck Group, Vitabiotics, William Ransom & Son Holdings Plc, Uni-Vite Healthcare and Health Made Easy Limited amongst others.

The report covers exhaustive analysis on:

Regional Analysis:

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/26233

Important insights present in the report:

See the original post:

High Demand for Anti-Aging Medicine from the Millennial Population to Foster the Growth of the Anti-Aging Medicine Market between 2018 2026 - 3rd...

New Trend: Spinal Muscular Atrophy Medicine Market key drive and Regional Share, Trends, Competitor Analysis to 2026| Astellas Pharma Inc., AveXis,…

Posted on by

LOS ANGELES, United States: QY Research has recently published a report, titled Global Spinal Muscular Atrophy Medicine Market Research Report 2020. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Spinal Muscular Atrophy Medicine market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Spinal Muscular Atrophy Medicine market include: , Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS, Ionis Pharmaceuticals, Inc., Longevity Biotech, Inc, Neurodyn Inc., Neurotune AG, Novartis AG, Sarepta Therapeutics, Inc., Voyager Therapeutics, Inc., Vybion, Inc., WAVE Life Sciences Ltd.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1984794/global-spinal-muscular-atrophy-medicine-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Spinal Muscular Atrophy Medicine market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Spinal Muscular Atrophy Medicine Market Segment By Type:

LMI-070ND-602NT-1654NusinersenNXD-30001Others

Global Spinal Muscular Atrophy Medicine Market Segment By Application:

HospitalClinicOthers

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Spinal Muscular Atrophy Medicine market.

Key companies operating in the global Spinal Muscular Atrophy Medicine market include , Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS, Ionis Pharmaceuticals, Inc., Longevity Biotech, Inc, Neurodyn Inc., Neurotune AG, Novartis AG, Sarepta Therapeutics, Inc., Voyager Therapeutics, Inc., Vybion, Inc., WAVE Life Sciences Ltd.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1984794/global-spinal-muscular-atrophy-medicine-market

TOC

1 Spinal Muscular Atrophy Medicine Market Overview1.1 Product Overview and Scope of Spinal Muscular Atrophy Medicine1.2 Spinal Muscular Atrophy Medicine Segment by Type1.2.1 Global Spinal Muscular Atrophy Medicine Sales Growth Rate Comparison by Type (2021-2026)1.2.2 LMI-0701.2.3 ND-6021.2.4 NT-16541.2.5 Nusinersen1.2.6 NXD-300011.2.7 Others1.3 Spinal Muscular Atrophy Medicine Segment by Application1.3.1 Spinal Muscular Atrophy Medicine Sales Comparison by Application: 2020 VS 20261.3.2 Hospital1.3.3 Clinic1.3.4 Others1.4 Global Spinal Muscular Atrophy Medicine Market Size Estimates and Forecasts1.4.1 Global Spinal Muscular Atrophy Medicine Revenue 2015-20261.4.2 Global Spinal Muscular Atrophy Medicine Sales 2015-20261.4.3 Spinal Muscular Atrophy Medicine Market Size by Region: 2020 Versus 20261.5 Spinal Muscular Atrophy Medicine Industry1.6 Spinal Muscular Atrophy Medicine Market Trends 2 Global Spinal Muscular Atrophy Medicine Market Competition by Manufacturers2.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2015-2020)2.2 Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2015-2020)2.3 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2015-2020)2.4 Manufacturers Spinal Muscular Atrophy Medicine Manufacturing Sites, Area Served, Product Type2.5 Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends2.5.1 Spinal Muscular Atrophy Medicine Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key Spinal Muscular Atrophy Medicine Players (Opinion Leaders) 3 Spinal Muscular Atrophy Medicine Retrospective Market Scenario by Region3.1 Global Spinal Muscular Atrophy Medicine Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global Spinal Muscular Atrophy Medicine Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country3.3.1 North America Spinal Muscular Atrophy Medicine Sales by Country3.3.2 North America Spinal Muscular Atrophy Medicine Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe Spinal Muscular Atrophy Medicine Market Facts & Figures by Country3.4.1 Europe Spinal Muscular Atrophy Medicine Sales by Country3.4.2 Europe Spinal Muscular Atrophy Medicine Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific Spinal Muscular Atrophy Medicine Market Facts & Figures by Region3.5.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region3.5.2 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country3.6.1 Latin America Spinal Muscular Atrophy Medicine Sales by Country3.6.2 Latin America Spinal Muscular Atrophy Medicine Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa Spinal Muscular Atrophy Medicine Market Facts & Figures by Country3.7.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country3.7.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global Spinal Muscular Atrophy Medicine Historic Market Analysis by Type4.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2015-2020)4.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2015-2020)4.3 Global Spinal Muscular Atrophy Medicine Price Market Share by Type (2015-2020)4.4 Global Spinal Muscular Atrophy Medicine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Spinal Muscular Atrophy Medicine Historic Market Analysis by Application5.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2015-2020)5.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2015-2020)5.3 Global Spinal Muscular Atrophy Medicine Price by Application (2015-2020) 6 Company Profiles and Key Figures in Spinal Muscular Atrophy Medicine Business6.1 Astellas Pharma Inc.6.1.1 Corporation Information6.1.2 Astellas Pharma Inc. Description, Business Overview and Total Revenue6.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.1.4 Astellas Pharma Inc. Products Offered6.1.5 Astellas Pharma Inc. Recent Development6.2 AveXis, Inc.6.2.1 AveXis, Inc. Corporation Information6.2.2 AveXis, Inc. Description, Business Overview and Total Revenue6.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.2.4 AveXis, Inc. Products Offered6.2.5 AveXis, Inc. Recent Development6.3 Bioblast Pharma Ltd.6.3.1 Bioblast Pharma Ltd. Corporation Information6.3.2 Bioblast Pharma Ltd. Description, Business Overview and Total Revenue6.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.3.4 Bioblast Pharma Ltd. Products Offered6.3.5 Bioblast Pharma Ltd. Recent Development6.4 Cytokinetics, Inc. 246.4.1 Cytokinetics, Inc. 24 Corporation Information6.4.2 Cytokinetics, Inc. 24 Description, Business Overview and Total Revenue6.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.4.4 Cytokinetics, Inc. 24 Products Offered6.4.5 Cytokinetics, Inc. 24 Recent Development6.5 F. Hoffmann-La Roche Ltd.6.5.1 F. Hoffmann-La Roche Ltd. Corporation Information6.5.2 F. Hoffmann-La Roche Ltd. Description, Business Overview and Total Revenue6.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.5.4 F. Hoffmann-La Roche Ltd. Products Offered6.5.5 F. Hoffmann-La Roche Ltd. Recent Development6.6 Genethon6.6.1 Genethon Corporation Information6.6.2 Genethon Description, Business Overview and Total Revenue6.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.6.4 Genethon Products Offered6.6.5 Genethon Recent Development6.7 Genzyme Corporation6.6.1 Genzyme Corporation Corporation Information6.6.2 Genzyme Corporation Description, Business Overview and Total Revenue6.6.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.4.4 Genzyme Corporation Products Offered6.7.5 Genzyme Corporation Recent Development6.8 GMP-Orphan SAS6.8.1 GMP-Orphan SAS Corporation Information6.8.2 GMP-Orphan SAS Description, Business Overview and Total Revenue6.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.8.4 GMP-Orphan SAS Products Offered6.8.5 GMP-Orphan SAS Recent Development6.9 Ionis Pharmaceuticals, Inc.6.9.1 Ionis Pharmaceuticals, Inc. Corporation Information6.9.2 Ionis Pharmaceuticals, Inc. Description, Business Overview and Total Revenue6.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.9.4 Ionis Pharmaceuticals, Inc. Products Offered6.9.5 Ionis Pharmaceuticals, Inc. Recent Development6.10 Longevity Biotech, Inc6.10.1 Longevity Biotech, Inc Corporation Information6.10.2 Longevity Biotech, Inc Description, Business Overview and Total Revenue6.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.10.4 Longevity Biotech, Inc Products Offered6.10.5 Longevity Biotech, Inc Recent Development6.11 Neurodyn Inc.6.11.1 Neurodyn Inc. Corporation Information6.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.11.4 Neurodyn Inc. Products Offered6.11.5 Neurodyn Inc. Recent Development6.12 Neurotune AG6.12.1 Neurotune AG Corporation Information6.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.12.4 Neurotune AG Products Offered6.12.5 Neurotune AG Recent Development6.13 Novartis AG6.13.1 Novartis AG Corporation Information6.13.2 Novartis AG Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.13.4 Novartis AG Products Offered6.13.5 Novartis AG Recent Development6.14 Sarepta Therapeutics, Inc.6.14.1 Sarepta Therapeutics, Inc. Corporation Information6.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.14.4 Sarepta Therapeutics, Inc. Products Offered6.14.5 Sarepta Therapeutics, Inc. Recent Development6.15 Voyager Therapeutics, Inc.6.15.1 Voyager Therapeutics, Inc. Corporation Information6.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.15.4 Voyager Therapeutics, Inc. Products Offered6.15.5 Voyager Therapeutics, Inc. Recent Development6.16 Vybion, Inc.6.16.1 Vybion, Inc. Corporation Information6.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.16.4 Vybion, Inc. Products Offered6.16.5 Vybion, Inc. Recent Development6.17 WAVE Life Sciences Ltd.6.17.1 WAVE Life Sciences Ltd. Corporation Information6.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.17.4 WAVE Life Sciences Ltd. Products Offered6.17.5 WAVE Life Sciences Ltd. Recent Development 7 Spinal Muscular Atrophy Medicine Manufacturing Cost Analysis7.1 Spinal Muscular Atrophy Medicine Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine7.4 Spinal Muscular Atrophy Medicine Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 Spinal Muscular Atrophy Medicine Distributors List8.3 Spinal Muscular Atrophy Medicine Customers 9 Market Dynamics9.1 Market Trends9.2 Opportunities and Drivers9.3 Challenges9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global Spinal Muscular Atrophy Medicine Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Type (2021-2026)10.1.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Type (2021-2026)10.2 Spinal Muscular Atrophy Medicine Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Application (2021-2026)10.2.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Application (2021-2026)10.3 Spinal Muscular Atrophy Medicine Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Region (2021-2026)10.3.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Region (2021-2026)10.4 North America Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)10.5 Europe Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)10.6 Asia Pacific Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)10.7 Latin America Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)10.8 Middle East and Africa Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source12.1 Methodology/Research Approach12.1.1 Research Programs/Design12.1.2 Market Size Estimation12.1.3 Market Breakdown and Data Triangulation12.2 Data Source12.2.1 Secondary Sources12.2.2 Primary Sources12.3 Author List12.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Visit link:

New Trend: Spinal Muscular Atrophy Medicine Market key drive and Regional Share, Trends, Competitor Analysis to 2026| Astellas Pharma Inc., AveXis,...

Global Pulmonary Arterial Hypertension (Pah) Medicine Market Trend Shows a Speedy Growth by 2027 According to Reportspedia Research – 3rd Watch News

Posted on by

Global Pulmonary Arterial Hypertension (Pah) Medicine Market Forecast(2020-2027) Research Report presents a comprehensive outline of Pulmonary Arterial Hypertension (Pah) Medicine industry states as well as Product Specification, Technology Development, and Key manufacturers. This study presents an in-depth analysis of market including Pulmonary Arterial Hypertension (Pah) Medicine Market share, CAGR status, market demand, and up to the present market trends with key market segments.

The Pulmonary Arterial Hypertension (Pah) Medicine Market report explores various features such as product scope, product market by application and by region, the market size for the precise product Type, sales and revenue by region forecast the Market size for various segments. The report provides detailed data concerning the most important factors (Strengths, Weaknesses, Opportunities, and Threats)of the Pulmonary Arterial Hypertension (Pah) Medicine market. The SWOT analysis gives a clear idea about the internal strengths and weaknesses, as well as its external opportunities and threats to the Pulmonary Arterial Hypertension (Pah) Medicine Market.

Request For Free Sample Report: @ https://www.reportspedia.com/report/-life-sciences/2015-2027-global-pulmonary-arterial-hypertension-(pah)-medicine-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/66013#request_sample

Following analysis are covered in this research including, SWOT analysis, Porters Five Forces analysis, qualitative and quantitative analysis, opportunity analysis, manufacturing cost analysis, and PESTLE analysis to give a complete understanding of the global Pulmonary Arterial Hypertension (Pah) Medicine market

Prominent players operating in the Global Pulmonary Arterial Hypertension (Pah) Medicine Market are:

Bayer HealthCareActelion PharmaceuticalsPfizerGlaxoSmithKlineArena PharmaceuticalsGilead SciencesUnited Therapeutics Corporation

The Type Coverage in the Market are:

Endothelin Receptor Antagonists (ERA)Prostacyclin And Prostacyclin AnalogsPhosphodiesterase 5 (PDE-5)

Market Segment by Applications, covers:

Secondary Pulmonary Hypertension (SPH)Primary Pulmonary Hypertension (PPH)

If you have any questions or need any customization in the report, Do Inquiry Here: https://www.reportspedia.com/report/-life-sciences/2015-2027-global-pulmonary-arterial-hypertension-(pah)-medicine-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/66013#inquiry_before_buying

Regional Analysis:

This section of this report includes region-wise and country-wise market size(in terms of Value and Volume) outlook and for the forecast period 2020 to 2027. The following are the top regions that consider this research.

Desirable feature Of The Pulmonary Arterial Hypertension (Pah) Medicine Industry Report:

Ask For Discount: https://www.reportspedia.com/discount_inquiry/discount/66013

Major Highlights Pulmonary Arterial Hypertension (Pah) Medicine Market Reports:

Executive Summary

Manufacturing Cost Structure Analysis

Key Figures of Major Manufacturers

Pulmonary Arterial Hypertension (Pah) Medicine Production and Capacity Analysis

Pulmonary Arterial Hypertension (Pah) Medicine Revenue Analysis

Pulmonary Arterial Hypertension (Pah) Medicine Price Analysis

View the Detailed [emailprotected] https://www.reportspedia.com/report/-life-sciences/2015-2027-global-pulmonary-arterial-hypertension-(pah)-medicine-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/66013#table_of_contents

See more here:

Global Pulmonary Arterial Hypertension (Pah) Medicine Market Trend Shows a Speedy Growth by 2027 According to Reportspedia Research - 3rd Watch News

An Australian doctor who wasn’t allowed to study medicine in Iran is drawing attention to the plight of Baha’is – SBS News

Posted on by

More than 250 medical professionals have joined an Australian doctor in his campaign to draw attention to the persecution of the Baha'i religious minority in Iran.

Joobin Hooshmand, an ophthalmology registrar working with NSW Health, launched an open letter this week amid fears the coronavirus crisis in the country would impact Baha'i inmates being held in overcrowded Iranian prisons.

The open letter, being circulated via Google Form, calls for the release of "all those who have been imprisoned due to their faith".At least 77 Baha'is have been arrested across eight Iranian provinces over recent weeks, it reads.

Doctors, dentists, nurses, optometrists, paramedics, physiotherapists, pharmacists, chiropractors, and psychologists are among those who have signed onto the letter, many of them Baha'is.

"As medical practitioners, we've seen first hand the effects of COVID on our patients," Dr Hooshmand said. "And there's a government that is putting people into harm, so I felt like this is something that's going to resonate with my fellow medical practitioners."

Dr Hooshmand, who is Baha'i, arrived in Australia as a refugee when he was 18 years old after deciding to leave Iran as the government does not permit members of the religious minority to study at university.

"For the past 40 years, none of the Baha'i children in Iran has been able to progress beyond high school, and I was one of them," he said."I want to bring international media attention to the plight of the Baha'is in Iran."

According to the United Nations, there are an estimated 350,000 Baha'is in Iran, making them the country's largest non-Muslim religious minority.

In a 2019 report, UNSpecial Rapporteur to Iran Javaid Rehman said adherents of the religion had suffered the "most egregious forms of repression, persecution, and victimisation".

Since the 1979 Iranian revolution, more than 200 Baha'is - regarded as "unprotected infidels" by Iranian authorities - have been executed "solely on the basis of their religious beliefs", the report continues.

The Middle Eastern country has been one of the hardest hit during the coronavirus pandemic. More than 279,000 cases and 14,600 deaths have been reported in Iran as of midday on Wednesday, according to the John Hopkins University tally.

Iran's leaders have estimated that up to 25 million people have been infected.

"This pandemic has made evident our interconnectedness as one humanity sharing a common home, where an outbreak of disease-causing pain and suffering in one part of the planet has implications for us all," the letter continued.

"At a time when every government should be focusing on protecting all its citizens, these Bahais, whose lives and livelihoods are under great strain, are being targeted solely due to their faith."

Originally posted here:

An Australian doctor who wasn't allowed to study medicine in Iran is drawing attention to the plight of Baha'is - SBS News

Keck Medicine Of USC Looking To Fill More Than 700 Positions – CBS Los Angeles

Posted on by

LOS ANGELES (CBSLA) The health care field has become more important than ever in the wake of the coronavirus pandemic, and one hospital group is looking to fill hundreds of positions across the Southland.

We have over 700 positions open here in our organization spanning from Orange County, Greater Los Angeles, all the way up to Palmdale, Glendale, Lisa Joins, Keck Medicine of USC human resources executive director, said.

Joins said Keck was not only looking to hire for its Southern California medical offices, but also at its three hospitals Keck Hospital, Norris Hospital and Verdugo Hills Hospital which are in need of people to fill a variety of roles.

Administrative-level positions, nursing positions, she said. We have LVN roles, IT, billing, finance, the whole gamut of positions that would be available in any industry, we have here at Keck Medicine of USC.

Those interested in entry-level positions will need at least a high school diploma or a GED, and the starting pay is $15 per hour. Among the perks of working for KECK USC is that those who get into USC could potentially go to school for free, Joins said.

We look for people who have energy, people who want to make a difference, she said. Were a great place to work, and we welcome everyone who would love to apply.

More information about careers at Keck Medicine of USC can be found online.

Go here to see the original:

Keck Medicine Of USC Looking To Fill More Than 700 Positions - CBS Los Angeles

New Movies, Sexual Misconduct Lawsuit Against UNL, High Number of Housing Valuation Protests and more Top Local News for Tuesday, July 21 – Omaha…

Posted on by

7/22/20 Day 30 ofPhase IIINationwide case trends

Support us by becoming a member and following us onTwitter, InstagramandFacebook

Fun, Guns, and Mum: New Stuff to Watch!

Three new sci-fi/horror-adjacent films recently dropped that weirdly explore oddly similar themes about the horrors of immortality/mortality and how empathy is the only way to fight the bogeyman.

View our guide to local resources atTheReader.com

Good morning,

Today we have stories about three new movies to take your mind off the pandemic that are available to stream from your home, nine UNL students who are suing the university over insufficient investigations into their reports of sexual harassment and property value protests reaching a 13-year-high this summer.

From our list ofthings to do during quarantine:

Scavenger Hunt!

Keep kids excited and learning about the home they live in by challenging them to find five items that begin with the letter A, ten things that are red, three things you can wear on your head.

Daily Comic

Check out more coverage online at TheReader.com

The Omaha Reader

4734 S 27th St #1

Omaha, NE 68107

More:

New Movies, Sexual Misconduct Lawsuit Against UNL, High Number of Housing Valuation Protests and more Top Local News for Tuesday, July 21 - Omaha...

Flatliners was Joel Schumachers attempt to touch the void – The Spool

Posted on by

Every month, we at The Spool select a filmmaker to explore in greater depth their themes, their deeper concerns, how their works chart the history of cinema and the filmmakers own biography.For July, we honor the chameleonic genre-bending of the recently-passed Joel Schumacher, who embraced camp thrills and pulp trash in equal measure. Read the rest of our coveragehere.

Last month, we lost visionary director Joel Schumacher. Losing any artist is a tragedy, but the idea of this one finally succumbing to the fate that so plagued his arrt makes it more sobering and haunting than most.

His works always had either undertones or overtones of immortality and death, what it means to die, what happens after. Better yet, what do you sacrifice in the pursuit of the knowledge of these things, and how does it alter those around you? Most famously, this could be seen in his work inThe Lost Boys. However, the film that seems to cut closer to Schumachers anxieties and philosophical inquiries was his 1990 science fiction film,Flatliners.

Starring a top of their game cast, the movie followed five Chicago medical students on their quest to see if anything exists after death. One of Nelson (Kiefer Sutherland), David (Kevin Bacon), Joe (William Baldwin), Randy (Oliver Platt), or Rachel (Julia Roberts) dieor flatlinefor a period of time. They then have the others bring them back and stabilize them. Ego and an insatiable lust for knowledge goading them on, the group gradually stays under longer and longer as the demons of their past bleed into hallucinations in their present.

Flatlinersposes a triad of uncomfortable thoughts about the human psyche after death. The group all saw things, but they all varied from person to person and seemed inexorably linked to their own strongest memories and desires. Unfortunately for them, the strongest abiding memories many humans have are rooted in personal guilt or trauma. For one it was being a serial cheater, for another the death of a parent, another the accidental deaths and/or bullying of their peers in childhood. They were all manifestations that follow them into their waking lives as they walk the razor edge between life and death in pursuit of absolute knowledge.

Furthermore, when one confronts and resolves this guilt and trauma, these hallucinations vanish. Does this mean that without them there will now be nothing to see when they die? Will a second-tier trauma replace it? A good memory? Or just a void? Did they really prove anything at all?

In the case of Rachels father (Benjamin Mouton), he shows up in a ghostly form, seemingly in limbo. Could this dimension be where all with unresolved burdens go? If this is true, that paints a horrible picture for the chronically mentally ill, murdered, and tortured. Its a purgatory of the worst memory thats haunted them all their lives because of things they couldnt control, even if they wanted to.

The lynchpin to this moral pondering is Nelson, our closest thing to a direct point of view. Hes the dashing mind with a deathwish in pursuit of fortune and glory and almost Odin-like omniscience. Hes also the one who suffers the most physically, mentally, and possibly even spiritually as his crimes are the most egregious of the five. Its fitting not only in the potential for that guilt to have been the true catalyst for his tests, but also in that cosmically. In all of human myth, those who seek the most hidden knowledge often pay the highest price.

From invincibility as an outward persona to the vulnerability expertly hidden underneath, it plays as a potential musing by Schumacher of his own hubris. Sutherland in general seemed to be a sort of avatar for Schumacher in his films. He was there to say some of the harder truths and show some of the darker sides of humanity that, perhaps, the filmmaker himself was trying himself to unpack, understand, and excise.

In this way, Nelson andThe Lost Boys David can be seen as two sides of the same coin, almost perfectly mirroring Schumachers thoughts on death and the afterlife. One is in an almost juvenile and viral time in his life, one in the desperate attempt by a creator to find meaning in the slow descent into age and mortality. In essence,The Lost Boysreveled in the hypothetical strength of physical immortality.Flatliners, however,agonized over the frightening stagnation of metaphysical eternity.

The Lost Boysreveled in the hypothetical strength of physical immortality.Flatliners, however,agonized over the frightening stagnation of metaphysical eternity.

This could be what makes Schumachers sudden passing so dour compared to other artists. He clearly wracked his brain over the possibilities of death, redemption, and guilt. There was even self-made eternal stagnation from which you can run but never hide. Did he have time to right the wrongs he felt haunted by? Did he assuage his guilt? Did he resolve the traumatic visions he may have manifested were he in the room with the doctors in the throes of their Mary Shelley-esque experimentation?

Or did he die in quiet dread of the thought of what awaited him? Thats the answer the group never really got, and that we all never really will. If you joined the Flatliners, what would you see? Would you be proud? Would you be haunted? Hopefully Schumacher found the answers he saught.

Samantha Schorsch is a freelance writer and editor and lifelong resident of Chicago. She graduated with an MFA in writing and publishing from DePaul University in 2017 and has been sharing her opinions and analyses loudly on the internet and in print ever since. She is also firmly on the Jason side of the eternal Freddy vs. Jason argument, when applicable.

Liked it? Take a second to support The Spool on Patreon!

Related

Visit link:

Flatliners was Joel Schumachers attempt to touch the void - The Spool

Netflixs The Old Guard: A revolutionary, ancient gay romance – Vox.com

Posted on by

One Good Thing is Voxs recommendations feature. In each edition, find one more thing from the world of culture that we highly recommend.

The Old Guard, Netflixs newest blockbuster, is actually multiple love stories in a big action flick coat.

Based on the 2017 comic book written by the indomitable Greg Rucka and drawn by Leandro Fernandez, The Old Guard is ostensibly about a group of killing machines who can never die. But its really about the aching loneliness of being a killing machine who can never die.

Andy (Charlize Theron), a.k.a. Andromache of Scythia, has been alive long enough to know this better than anyone. The story is set in the present day, but Andys birth predates the ancient Greeks. She has over time learned that the only way to survive forever is to never let mortals get too close to her. Booker, another of Andys fellow immortals, tells Andy from personal experience that watching your kids die isnt something you want to reckon with. And it becomes one of the first things Andy teaches Nile (KiKi Layne), the newest addition to her chosen family of immortal soldiers.

Joe (Marwan Kenzari) and Nicky (Luca Marinelli), the couple that rounds out Andys never-dying family, are the lucky ones among the group because they have each other, forever and always.

Joe and Nicky arent the main protagonists in director Gina Prince-Bythewoods film, but since the films release on July 10, theyre the characters who have garnered a lot of attention because of how rare it is that gay men are featured in action movies. Even rarer is that were allowed to watch Joe and Nicky share a passionate kiss and other physical moments of affection throughout the film.

And The Old Guard takes their love story a step further. Straight people are regularly part of myths and legends, but LGBTQ people rarely feature in them. The times that queerness does pop up in popular, mainstreamed ancient histories, myths, and legends, it can sometimes come across like its written in code, or is found buried in footnotes, or is glossed over as brotherly love or friendship, not romantic affection.

That The Old Guards Joe and Nicky are unapologetic about their love allows queer people, and gay men in particular, the opportunity to see that throughout all of history, weve been there all along and in such a mainstream, typically heteronormative medium, no less. That representation in itself is not just thrilling, but revolutionary.

Since the movies Netflix premiere, theres one scene in particular that viewers have discussed over and over, rising above the battle axes and bullets. Midway through the movie, the villains who are seeking to steal the secrets of immortality capture Joe and Nicky after an all-out assault on Andys team. While transporting them to the lab where scientists plan to poke, prod, and experiment on them, a security guard mocks Joe and Nicky, asking if theyre boyfriends. Its likely that to some queer people watching, the mocking isnt unlike stuff weve heard on playgrounds or even in adulthood.

Youre a child, Joe snaps back. Hes not my boyfriend. This man is more to me than you can dream. Hes the moon when Im lost in darkness, and warmth when I shiver in cold. And his kiss still thrills me even after a millennium. His heart overflows with a kindness of which this world is not worthy. I love this man beyond measure and reason. Hes not my boyfriend. He is all, and he is more.

Joes response is equal parts snappy retort and love poem. At its heart is a simple message: that straight people might not ever fully understand what its like to be gay and to find love. Their love is not better nor more profound, but innately different. Their love is forged from generations of being taught that its unnatural, forbidden, and wrong by a society that, for many centuries, has relegated queer people to the margins and encouraged us to be people we arent.

The Old Guard gets at this adversity through Andys own broken love story, another queer romance. Andy and Quynh fought together through thousands of battles, and its implied that the two womens love is more than just platonic. When captured and tortured for being witches, Quynh is separated from Andy and thrown into an iron coffin at the bottom of the ocean.

You are too powerful together, the guard tells Andy, as Quynh is pulled away.

The guard could have meant that their combined immortality was too frightening. But he also could have meant that these two women and their love for each other is something to be feared, too. From then on, Andy lives every day carrying the weight of losing Quynh.

Its so clear that neither the guard who separates Andy from Quynh nor the one who taunted Nicky and Joe can even begin comprehending that queer love is just as powerful as any other kind. It may not immediately look like a heterosexual romance, but it is no less meaningful.

Joes declaration of passion for Nicky also invites the viewer to imagine the thousand or more years theyve seen and spent together. I, for one, hope they got to see spectacular, silly, beautiful things. We learn that they met fighting on opposite sides of the Crusades, have been by each others side for so very long, and will ostensibly continue to endure even after all of us turn to dust.

Thankfully, Joe and Nickys mythic queerness is far from the only foray into the genre in fact, The Old Guard has a perfect complement in the novel The Song of Achilles.

A week before Netflix released The Old Guard, I was on vacation at home, because that is how we vacation now and finished reading Madeline Millers The Song of Achilles. I was already a fan of Millers after reading Circe, her retelling of the immortal witch and temptress from The Odyssey.

The Song of Achilles is Millers first novel, from 2012. She gives life to the myths of Achilles from his companion Patrocluss point of view, telling a story about love that endures when forces of nature, fate, and war are determined to tear you apart.

Growing up, I knew Achilles had that pesky foot thing and played a part in the Trojan War, but all I really knew about Patroclus was that he was really good friends with the very heterosexual Achilles in 2004s Troy.

Beyond that not-great movie, Achilles and Patrocluss homosexuality has been debated over and over, usually coming down to dissecting ancient Greek culture and the semantics of gay. Miller sees it as simpler than that.

I would also add, more specifically, that I think the culture is ready for the kind of love story that transcends gender and time, Miller said in a Q&A about the book on her website. I did not deliberately set out to tell a deliberately gay love story; rather, I was deeply moved by the love between these two characterswhose respect and affection for each other, despite the horrors around them, model the kind of relationship we all can aspire to.

Miller has an uncanny ability to make you nostalgic for voices youve never heard, places youve never been. Her novels leave you wistful for true love youve never had the chance to lose.

The Song of Achilles is something you should read if you think that The Old Guard, which spends most of its runtime focused on Andy teaching Nile about life, should have been about Joe and Nickys infinite love above all else. It expands on the themes touched upon in Joes speech and the supernatural aspect of immortality thanks to gods, goddesses, and deities.

But The Song of Achilles is easily beautiful enough to stand on its own. Though Miller says she didnt deliberately set out to create a gay love story, its a fantasy that unravels and justifies the feelings and vulnerability of the LGBTQ experience, and of gay men in particular. Just as The Old Guard does for new Netflix viewers or longtime comic book fans, this novel indulges the desire to want and be loved, no matter your sexuality. And The Old Guard and The Song of Achilles both reassure queer readers that weve always existed even when we havent always been seen in the ancient history books.

The Old Guard is streaming on Netflix.

Support Voxs explanatory journalism

Every day at Vox, we aim to answer your most important questions and provide you, and our audience around the world, with information that has the power to save lives. Our mission has never been more vital than it is in this moment: to empower you through understanding. Voxs work is reaching more people than ever, but our distinctive brand of explanatory journalism takes resources particularly during a pandemic and an economic downturn. Your financial contribution will not constitute a donation, but it will enable our staff to continue to offer free articles, videos, and podcasts at the quality and volume that this moment requires. Please consider making a contribution to Vox today.

View original post here:

Netflixs The Old Guard: A revolutionary, ancient gay romance - Vox.com

Parasite Joins Criterion in October with 4K Remaster, Black-and-White Edition, and More – IndieWire

Posted on by

The Criterion Collection has announced an October release date for its Parasite Blu-ray release, a fitting date as the release will mark the one-year anniversary of Bong Joon Hos U.S. theatrical release. The Criterion Parasite release includes not only a 4K remaster of the original film supervised by Bong Joon Ho himself, but also the movies much-touted black-and-white version and new audio commentary track with Bong and film critic Tony Rayns.

A zeitgeist-defining sensation that distilled a global reckoning over class inequality into a tour de force of pop-cinema subversion, Bong Joon Hos genre-scrambling black-comic thriller confirms his status as one of the worlds foremost filmmakers, Criterion wrote in a statement announcing the films October release date. A bravura showcase for its directors meticulously constructed set pieces, bolstered by a brilliant ensemble cast and stunning production design, Parasite cemented the New Korean Cinema as a full-fledged international force when it swept almost every major prize from Cannes to the Academy Awards.

Parasite made history at the Oscars at the beginning of 2020 by becoming the first foreign language film to take home top honors for Best Picture and Best Director. The film also won Academy Awards for Best Original Screenplay and Best International Feature Film. The movie joins fellow October 2020 Criterion releases such as John Berrys Claudine, Henry Kings The Gunfighter, Jean-Luc Godards Pierrot le fou, and Stephen Frears The Hit.

All of the special features included on the Parasite Criterion release are listed below.

New 4K digital master, approved by director Bong Joon Ho and director of photography Hong Kyung Pyo, with Dolby Atmos soundtrack on the Blu-ray New audio commentary featuring Bong and critic Tony Rayns Black-and-white version of the film with a new introduction by Bong, and Dolby Atmos soundtrack on the Blu-ray New conversation between Bong and critic Darcy Paquet New interviews with Hong, production designer Lee Ha Jun, and editor Yang Jinmo New program about the New Korean Cinema movement featuring Bong and filmmaker Park Chan Wook (Oldboy) Cannes Film Festival press conference from 2019 featuring Bong and members of the cast Master class featuring Bong from the 2019 Lumire Festival in Lyon, France Storyboard comparison Trailers PLUS: An essay by critic Inkoo Kang

Criterion

Sign Up: Stay on top of the latest breaking film and TV news! Sign up for our Email Newsletters here.

Read more here:

Parasite Joins Criterion in October with 4K Remaster, Black-and-White Edition, and More - IndieWire

Talking to my children about racism has become much more complicated – The Globe and Mail

Posted on by

Fayeque Townsend-Rahman is a Canadian filmmaker. His first film, Necessary Illusions, won the Visionary Award at the D.C. Independent Film Festival.

Months of isolation elapsed, exposing enough of our vulnerabilities to bring us together as a species. But nobody expected what came: intimately witnessing the dark underbelly of what humans can do to each other, as we saw with the police killing of George Floyd in Minneapolis.

I am an ethnic minority (I hope thats the right term) or racialized Canadian (a new term Ive learned). I am the father of two biracial children. My wife is an Anglo-Saxon Haligonian. To many, we epitomize neo-Canadian society and culture.

Story continues below advertisement

Diversity is said to be this countrys strength. But a recent YouGov study showed that 72 per cent of Canadians believe racism is a serious problem in this country. However, 42 per cent didnt agree wholeheartedly, selecting the somewhat agree option. Indeed, 25 per cent disagreed (strongly or somewhat disagreed).

I find this fascinating. It shows that we are either conflicted about what racism entails or have citizens with exceptional self-awareness. Until recently, I would have bet on the latter because were Canadian.

Since the tragedy in Minneapolis, I have had a tough time talking to my children about their future. Statistics highlighting how the Black community is disproportionately discriminated against are painful but dont affect those of my colour as intensely. But I have been left humiliated, defeated and physically scarred simply because of the body I was born into.

Experiencing racism is a natural part of my existence.

Living in Italy in the eighties, xenophobia was (and arguably still is) a cultural norm. It was clear as day, with all the kids hanging out under fascist graffiti made by organized groups of violent footfall fans, the ultras. As a fluent Italian speaker, I could have easily passed as a regular Italian kid but for the colour of my skin.

In the nineties, I had the privilege of attending a posh boarding school in England. By the time I graduated, I just accepted myself as a Paki. I even called my brown friends by the slur. I remember a South Asian student being nicknamed Easter. I cant remember his real name because he was called Easter from the age of 13 until he left the school as an adult. Why? Because the French word for Easter is Pques.

At the time, racism was normalized.

Story continues below advertisement

These anecdotes are just the soft tip of the iceberg. But I am still alive. And here in Canada, I have experienced far fewer moments of intolerance than I have anywhere else.

That would have been my message for my children had the social zeitgeist not shifted after those fateful eight minutes and 46 seconds for Mr. Floyd and had the Amy Cooper incident, in which a white woman falsely claimed she was threatened by a Black man in Central Park, not flooded social media.

Nobody can minimize the atrocity committed in Minneapolis. Yet, as a person of colour, I am now more terrified of people like Ms. Cooper than I am of being killed by a police officer.

The same YouGov study I cited above asked pointed questions about race. More than 50 per cent of Canadians believe that preferring to live in a community that is mostly or exclusively the same race as them is not a racist scenario. According to a recent article by CBC, Canadians are among the most active in online, right-wing extremism more than users in the U.S. and Britain. Last year, Global News cited a report by the Environics Institute for Survey Research suggesting that more than half of Black and Indigenous Canadians reported being discriminated against 40 per cent said it happened at work.

These figures tell a complicated story. What frightens me is that my daily interactions in my community, at work or at the pub have a statistical probability of being racially charged. And there is no uniform to signal impending danger.

I would never have ascribed bigotry to Ms. Cooper, a university-educated person with an impressive rsum. She could be my boss, my colleague, a fellow parent or my childrens teacher. Yet we watched her weaponize the police with absolute racial intent. She now represents an unknown enemy.

Story continues below advertisement

Instagram posts supporting Black Lives Matter and corporate e-mails about intolerance are fancy. But will todays movement be remembered? After all, my children dont know who Rodney King is. Most people have forgotten Eric Garner and Botham Jean. Will Mr. Floyd pass into our latent history of racial pain?

To my kids, I can only say: Honour your heritage, because it will define you throughout your life. Remember the history of those who have fallen to the evil of racism. Have the courage to document injustice but, most of all, find the courage to stand up for human dignity no matter the cost.

Keep your Opinions sharp and informed. Get the Opinion newsletter. Sign up today.

Read the rest here:

Talking to my children about racism has become much more complicated - The Globe and Mail